Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ACZ885 (canakinumab) for efficacy, safety and tolerability in pediatric patients with Cryopyrin-associated periodic syndromes, includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Familial Cold Autoinflammatory Syndrome
• Muckle-wells Syndrome
• Neonatal-onset Multisystem Inflammatory Disease

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2015-08-18